Pharmacokinetic Parameters Clinical Uses Primary treatment of type 2 diabetes mellitus to reduce HbAc Chronic weight management in obesity or overweight individuals with risk factors Reduces risk of major adverse cardiovascular events in high-risk diabetic patients Adverse Effects Common: nausea, diarrhea, constipation, vomiting Less common: injection-site reactions, headache, dizziness Rare risk: pancreatitis
This dual action improves appetite control and insulin response
Cytokine levels were also measured in the mycobacteria-infected in vitro granuloma supernatants to determine the effects of in vitro PZA + in vivo GSH treatments and in vitro INH + in vivo GSH treatments in altering the levels of these cytokines
In the STEP 1 trial (semaglutide 2.4 mg for obesity), participants lost ~15% of their body weight on average, but roughly 45% of that weight loss came from lean tissue
These include: Pain, redness, or swelling at the injection site Bruising or hardening of tissue (induration) Itching or warmth around the injection area Temporary discolouration of the skin These localised reactions typically resolve within 2472 hours
10.1152/ajpgi.1999.277.2.G333 Am J Physiol
